Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
Date:10/11/2011

CAMBRIDGE, Mass., Oct. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel (Taxol®) in the neoadjuvant setting of HER2-negative breast cancer patients.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 2 study is designed to evaluate whether the combination of MM-121 with paclitaxel is more effective than treatment with paclitaxel alone when administered as part of a neoadjuvant treatment regimen in HER2-negative, locally advanced breast cancer patients. A total of 200 patients are expected to be enrolled in the study. Following treatment with MM-121 and paclitaxel, or paclitaxel alone, patients will receive standard treatment with doxorubicin and cyclophosphamide and monitored until surgical resection. Multiple sites in North America are currently expected to participate in this study. The first patient was enrolled at Texas Oncology - Memorial City.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043,
kgallagher@merrimackpharma.com
Betsy Stevenson,
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
2. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
3. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
4. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
7. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
8. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
9. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
10. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
11. OncoMed Pharmaceuticals Names Dr. Jakob Dupont VP Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Kindred Hospital Houston Northwest, ... the opening of its new outpatient wound healing ... to people with chronic, hard to heal wounds. ... lead to amputation, lower leg wounds related to ... closure, and traumatic injury wounds which are complex ...
(Date:7/11/2014)... York , July 11, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... MRI Medical Inc. is changing its name to Xeridiem ... plan. "Although we,re changing our name, we ... superior design, development, and manufacturing services that we,ve provided ... Devices, Inc.,s President. "Our mission remains the same - to ...
... Aerotel Medical Systems , a leading global supplier ... showcase its mobile health (mHealth) and other telemedicine solutions at ... Spain from February 14-17 at Hall 2, booth 2C12. ... healthcare providers around the world to reduce costs and improve ...
Cached Medicine Technology:MRI Medical Inc. Changing Name to Xeridiem Medical Devices, Inc. 2Aerotel to Present Mobile Health and Telemedicine Solutions at Mobile World Congress 2011 2
(Date:7/11/2014)... July 11, 2014 The Europe Well Intervention ... in Europe with analysis and revenue forecast. The well intervention ... $2.4 billion in 2013 to $3.4 billion by 2018, at ... through the TOC of the Europe Well Intervention Market report, ... also provides a glimpse of the segmentation in the Europe ...
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 Utilizing ... ’s own, Dr. William Koenig, has topped a record ... peers, he has performed over 400 successful procedures without ... Dr. Koenig is well known across the country for ... exceptional safety record has long been the foundation for ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... 2014 (HealthDay News) -- U.S. health officials have concluded ... to live anthrax during a safety mishap last month. ... Prevention officials have announced a moratorium on the transfer ... labs. In a report issued Friday, the CDC ... sure a similar incident doesn,t occur again. Last month, ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5
... responding to the devastation across Greece caused by this ... series of crisis map products based on satellite acquisitions ... assessment efforts following the activation of the International Charter ... people were killed and thousands left homeless in the ...
... 21 Baxa Corporation, a leading,provider of systems ... announces the addition of two new international product,distributors. ... Colombia and Pentafarma & Co. in The Dominican ... reach and expand product promotion in South,America and ...
... from DCM and Split Rock Partners, PALO ALTO, ... of its website. Caring.com will offer original "how,to" guides, ... and a community of people in caring situations, to ... million adults who are,caring for an aging relative in ...
... scientific peer review, will gather in Helsinki on 27 September ... from the fourth and final Call of the European Young ... to create teams in Europe to focus on cutting-edge science. ... from around the world to create their own research teams ...
... drugs plus insulin works best, researchers say , , FRIDAY, ... tell which insulin-plus-drug regimen might best control type 2 ... the three strategies tested coming out on top. , ... in the study can be recommended" as being superior ...
... Waltham, MA -- Brandeis neuroscientist Gina Turrigiano has been ... Award, a five-year grant totaling $2.5 million. She is ... competitive award. , According to NIH, the award ... who propose pioneering approaches to major challenges in biomedical ...
Cached Medicine News:Health News:Greeks get space-based help in wake of deadly fires 2Health News:Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic 2Health News:New Resource for Taking Care of Aging Parents Available in Beta 2Health News:New Resource for Taking Care of Aging Parents Available in Beta 3Health News:2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki 2Health News:2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki 3Health News:No Clear Winner in Diabetes Treatment Trial 2Health News:No Clear Winner in Diabetes Treatment Trial 3
Comfort Wrist Immobilizer with thumb abduction. 8"L, soft, padded comfort-type wrist immobilizer with dorsal metal stay. The thumb is held in abduction and splintered with a short metal stay....
... Splint immobilizes and positions the elbow at ... less prominent. Restricts full extension and flexion ... and helps prevent pain and irritation due ... and post-cast removal. Rigid, high-density beige polyethylene ...
... is constructed of a durable heat moldable thermoplastic ... tendons of the hand and fingers from stress ... the later stages of the healing process. , ... and positions the wrist at 30° of flexion, ...
Combination Oppenheimer with Knuckle Bender - to dorsiflex wrist and flex MCP joints; includes two attachments to extend/flex distal finger joints....
Medicine Products: